U.S. Department of Health & Human Services
National Institutes of Health
NCATS
Return Home
Inxight
Drugs
Search Substances
Home
Browse Drugs
US Approved Drugs
Marketed Drugs
Investigational Drugs
All Substances
Search
Structure Search
Sequence Search
Downloads
About
Search Substances
SATRALIZUMAB
YB18NF020M
US Approved Rx (2020)
First approved in 2020
General
Names
12
Classification
3
Identifiers
10
Subunits
4
Related Substances
1
SATRALIZUMAB
YB18NF020M
US Approved Rx (2020)
First approved in 2020
General
Approval Year
2020
742
Names
12
Show
5
20
100
All
entries
Name
Type
Language
Name
Type
Language
SATRALIZUMAB
Official Name
English
SA237
Code
English
SATRALIZUMAB [USAN]
Common Name
English
SATRALIZUMAB [MI]
Common Name
English
HUMANISED ANTI-IL-6 RECEPTOR MONOCLONAL ANTIBODY
Common Name
English
Showing 1 to 5 of 12 entries
Previous
1
2
3
Next
Classification
3
Show
5
20
100
All
entries
Classification Tree
Code System
Code
Classification Tree
Code System
Code
Biological Agent
Pharmacologic Substance
[C1909]
Biological Agent
[C307]
Monoclonal Antibody
NCI_THESAURUS
C20401
Positive
EU ORPHAN DRUG
Positive
Treatment of neuromyelitis optica spectrum disorders
EU-Orphan Drug
EU/3/16/1680
Immunotherapeutic Agent
Pharmacologic Substance
[C1909]
Immunotherapeutic Agent
[C308]
Immunosuppressant
NCI_THESAURUS
C574
Showing 1 to 3 of 3 entries
Previous
1
Next
Identifiers
10
Show
5
20
100
All
entries
Code System
Code
Type
Description
Code System
Code
Type
Description
DAILYMED
YB18NF020M
PRIMARY
RXCUI
2391541
PRIMARY
SMS_ID
100000181406
PRIMARY
USAN
DE-75
PRIMARY
FDA UNII
YB18NF020M
PRIMARY
Showing 1 to 5 of 10 entries
Previous
1
2
Next
Subunits
4
Subunit 0
>SUBUNIT_0
Subunit 1
>SUBUNIT_1
Subunit 2
>SUBUNIT_2
Subunit 3
>SUBUNIT_3
Related Substances
1
ACTIVE MOIETY
YB18NF020M
SATRALIZUMAB
